Source: Eur Respir J 2016; 47:1758-1766
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Tiberi Simon, Sotgiu Giovanni, D'Ambrosio Lia, Centis Rosella, Abdo Arbex Marcos, Alarcon Arrascue Edith, Alffenaar Jan Willem, Caminero Jose A., Gaga Mina, Gualano Gina, Skrahina Alena, Solovic Ivan, Sulis Giorgia, Tadolini Marina, Alarcon Guizado Valentina, De Lorenzo Saverio, Roby Arias Aurora Jazmín, Scardigli Anna, Akkerman Onno W., Aleksa Alena, Artsukevich Janina, Auchynka Vera, Bonini Eduardo Henrique, Chong Marín Félix Antonio, Collahuazo López Lorena, de Vries Gerard, Dore Simone, Kunst Heinke, Matteelli Alberto, Moschos Charalampos, Palmieri Fabrizio, Papavasileiou Apostolos, Payen Marie-Christine, Piana Andrea, Spanevello Antonio, Vargas Vasquez Dante, Viggiani Pietro, White Veronica, Zumla Alimuddin, Migliori Giovanni Battista. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J 2016; 47:1758-1766

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB Source: Eur Respir J 2016; 47: 1235-1243 Year: 2016 Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study Source: Eur Respir J, 49 (5) 1700387; 10.1183/13993003.00387-2017 Year: 2017 Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021 Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB Source: Eur Respir J 2013; 41: 1386-1392 Year: 2013 Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective Source: Eur Respir J 2010; 35: 936-938 Year: 2010 Comparison of efficacy and safety of fixed-dose combination regimen versus separate drugs for treatment of tuberculosis Source: International Congress 2019 – Insights into paediatric bronchology Year: 2019 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis Source: Eur Respir J 2012; 40: 1430-1442 Year: 2012 Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601799; DOI: 10.1183/13993003.01799-2016 Year: 2017 Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017 Year: 2017 Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB Source: Eur Respir J 2016; 47:1581-1584 Year: 2016 The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009 Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China Source: Eur Respir J 2015; 45: 161-170 Year: 2015 Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China Source: Eur Respir J 2016; 47:1591-1592 Year: 2016 Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB Source: ERJ Open Res, 5 (2) 00046-2019; 10.1183/23120541.00046-2019 Year: 2019 Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016